@article{ATM21814,
author = {Bryan C. Ulrich and Nicolas Guibert},
title = {Non-invasive assessment of tumor PD-L1 status with circulating tumor cells},
journal = {Annals of Translational Medicine},
volume = {6},
number = {Suppl 1},
year = {2018},
keywords = {},
abstract = {Now FDA-approved in the treatment of over ten malignancies, checkpoint blockade agents have transformed the treatment of cancer. These agents work by inhibiting the PD-1/PD-L1 interaction between cytotoxic T cells and tumor cells, an interaction which promotes immune evasion. PD-L1 expression levels by tumor cells, as assessed by tissue biopsy, is currently the most well-validated and clinically used predictive biomarker of response to checkpoint blockade agents (1,2). However, PD-L1 level is known to be an imperfect biomarker, and some FDA approvals do not set a PD-L1 expression level threshold to determine patient candidacy for checkpoint blockade.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/21814}
}